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Aim: The use of dexamethasone (DEX) in mesenchymal cell culture induces osteoblastic 
differentiation and, consequently, formation of mineralized tissues. Tissue engineering 
proposes the development of therapeutic strategies aimed at structural and functional 
regeneration of biological tissues. In this sense, cell characterization in vitro is critical 
to ensure the development of such techniques. Our objective was to evaluate the 
osteoinductive effect of DEX administered as a preoperative medication in primary cell 
culture of human dental pulp stem cell. Methodology: Cells from the third molar pulp 
were divided into two experimental groups, each with two preoperative medication 
protocols used in dental practice and differentiated by the intake of DEX in one of 
them. The assessment of proliferation, differentiation and viability through trypan 
blue, methylthiazol tetrazolium, and von Kossa and alizarin red assays, respectively, 
were held within fixed intervals: 7, 14, 21 and 28 days. Conclusion: This study has 
shown that DEX may influence in vitro human dental pulp stem cell behavior.
Lay abstract: Dexamethasone (DEX) is often used as a preoperative drug in dental 
surgeries because it reduces pain and has favorable effects on other symptoms 
caused by the surgery. Additionally, when used in cell culture, its osteoinductor effect 
is observed. In vitro cell characterization is critical to ensure the development of 
therapeutic strategies used in tissue engineering. In this sense, this study used two 
preoperative medication protocols regularly used in dental practice. In Protocol A, 
patients did not intake DEX; in Protocol B, patients took in tablets of DEX. It was 
possible to assess in vitro behavior of human dental pulp stem cells by applying those 
protocols.
First draft submitted: 15 November 2016; Accepted for publication: 7 February 2017; 
Published online: 03 April 2017
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The development of regenerative medicine 
provides a viable alternative to the treatment 
of tissue loss caused by congenital or degen-
erative traumatic injuries. Tissue engineer-
ing is an interdisciplinary field that seeks to 
regenerate biological tissues as described in 
studies conducted in the field of biological 
sciences and engineering [1,2] in order to offer 
the ultimate solution to organ failure [2,3]. 
The use and association of isolated cells and 
bio materials are the main therapeutic strat-
egies in tissue engineering, and an accurate 
interaction between them is essential [1]. The 
regenerative capacity of third molar cells and 
their pluripotentiality have boosted their 
use in regenerative medicine [4]. Further-
more, studies have proven that it is possible 
to develop biological tissues from these cells, 
which are capable of holding all the events 
associated with the process [5–7]. The appli-
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cation of the third molar cell culture technique starts 
immediately after the patient’s tooth is extracted; 
some tooth  development stages are more favorable for 
 culture [8].
When an individual undergoes a more invasive pro-
cedure, an increased amount of trauma in the surgical 
site and surrounding tissues occurs. Thus, the use of 
preoperative medications in order to reduce the sur-
gery trauma and postoperative pain becomes necessary 
and should be a routine in dental practice [9]. Regard-
ing preoperative medication, it has been observed that 
orally administered amoxicillin, an effective antibiotic, 
reduces the incidence of alveolitis, improves mouth 
opening limitation after surgery [10] and prevents 
postoperative wound infection [11]. Likewise, dexa-
methasone (DEX), a synthetic glucocorticoid [12,13], 
is used as an anti-inflammatory drug and considered 
a long-acting steroid, whose synthesis occurs in the 
adrenal cortex [14]. When DEX is administered, pain 
reduction occurs because the drug inhibits the release 
of mediators, such as lymphokines, prostaglandins 
(PGs), serotonin and bradykinin into the injured tis-
sue [11]. Furthermore, glucocorticoids are effective 
agents in reducing postoperative consequences, such 
as pain, swelling and trismus [9,11]. At present, it is 
known that DEX effects start immediately after the 
traumatic effects of surgery; therefore, this drug should 
be administered 1 h prior to the surgical procedure [11]. 
This glucocorticoid acts at early stages as well as late 
stages of the osteogenic differentiation and accelerates 
osteoblast maturation; however, the mechanisms are 
still unclear [12]. In addition to its anti-inflammatory 
properties, DEX is also added to culture media due to 
its low cost and good results as it induces osteoblast 
differentiation of mesenchymal stem cells (MSCs) [12] 
and osteogenic development [15].
Nevertheless, it is important to know whether this 
drug, when orally administered, will produce the same 
osteoinductive effect as when it is added directly to 
culture media. In this context, the aim of this study 
was to evaluate the osteoinductive effect of DEX when 
administered as a preoperative medication in primary 
cell culture of dental pulp.
Materials & methods
This research was approved by the Universidade Fed-
eral de São Paulo (UNIFESP) Ethical Committee 
under number 72518. It was designed as a primary, 
interventional, experimental, prospective, analytic and 
comparative study. In accordance with this design, six 
third molars were obtained from three human volun-
teers and collected from private clinics after extrac-
tion procedure. Informed consent was obtained for all 
biological tissues. Inclusion criteria for teeth selection 
were: intraosseous third molar tooth of healthy sub-
jects, subjects without chronic use of any drug treat-
ment whatsoever, subjects who lacked hypersensitiv-
ity to any of the drugs used (amoxicillin and DEX), 
third molars in stages 2–3 of development according to 
Duailibi et al. [8] rating and those who agreed to sign 
the informed consent. Exclusion criteria: teeth needing 
removal, dental anomaly, subjects with infectious or 
systemic diseases, patients with either a contaminated 
third molar tooth or near a contaminated area with 
coronary exposure to the oral environment.
Volunteers underwent two surgeries so that two 
samples could be obtained. Thus, two surgical pro-
cedures were performed on each patient: the upper 
right third molar was extracted at the first surgical 
session, and the lower left third molar, at the second 
session. This way, masticatory and swallowing func-
tions would not be affected, and postoperative recov-
ery would be easier. At the first surgical procedure, 
Protocol A (no DEX) was applied; at the second surgi-
cal session, Protocol B (with DEX). In Protocol A, the 
drug consisted of 4 amoxicillin 500 mg tablets (anti-
biotics), while Protocol B was 4 amoxicillin 500 mg 
tablets (antibiotics) + 14 mg DEX tablet (steroidal 
anti-inflammatory drug [SAID]) orally 1 h prior to 
surgery. The two protocols in question have been used 
at universities and by professional dentists in their 
dental practice for many years now and aim to reduce 
the effects of postoperative trauma, such as edema, 
trismus, limitation of mouth opening, among others. 
Thus, there was no distinction among the  benefits 
provided to the patient.
After surgery, the tooth was placed in a falcon tube 
with Hank’s Balanced Salt Solution (LGC Biotecno-
logia, Brazil) medium for preservation, then trans-
ported to a Petri dish, and finally the explant tech-
nique using the tooth pulp. Following, the teeth were 
washed up two- to three-times with Hank’s Balanced 
Salt Solution, and the dental pulp was removed for 
explant performance. The dental pulp was fragmented 
with scalpel blades number 13, MED BLADE® 
(Jiangsu Xuyi Kangning Medical, China) allocated 
in Petri plate (Sigma-Aldrich, São Paulo, Brazil) in 
1 mm dimensions. The explant pieces were placed into 
6-well culture plates, and 1 ml of culture medium was 
added Dulbecco’s Modified Eagle’s medium/Ham’S 
F12 1:1 (Ham’s F-12 nutrient mixture, LGC Bio-
tecnologia) to each well and supplemented with 5% 
fetal bovine serum (FBS) and 0.5% penicillin antibi-
otics (LGC Biotecnologia) and streptomycin (LGC 
Biotecno logia). Cultivation occurred until migration 
and full cells confluence. The culture medium was 
changed every 3 days using the medium previously 
described. The cells were maintained in an incubator 
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at a relative humidity of 95% oxygen and 5% carbon 
dioxide at a temperature of 37°C, where they were 
grown until the second passage, reaching confluency 
with a required total of 41.6 × 106 cells.
Cell proliferation
Homogenization of the cell pellet from the second pas-
sage was performed in culture medium made up using 
successive aspirations and ejections with a pipette 
(Sarstedt®, Inc., NC, USA) and electronic pipettor 
Gilson® (Gilson SAS, Villiers-le-Bel, France). A total 
of 10 ml of the concentrated cell homogenate were 
withdrawn with a micropipette and a disposable tip; 
then, they were transferred to an Eppendorf (Sarstedt, 
Inc.) and mixed with the same volume of trypan blue 
dye at 0.4% (Sigma-Aldrich), and homogenized again. 
Following this step, 10 μl of the colored solution were 
pipetted and transferred to the chamber slide for pro-
liferation assessment. The sample was introduced in 
the automatic cell counter (Countess®, Invitrogen, 
São Paulo, Brazil), which calculated the total number 
of both living and dead cells. This procedure was per-
formed after cell expansion and at the end of all tryp-
sinizations. All T75 bottles (Sarstedt, Inc.)  initiated 
with 2 × 106 cells before the  experimental stages.
Cell viability assay: methylthiazol 
tetrazolium
We used the methylthiazol tetrazolium (MTT) 
(Sigma, Brazil) assay to assess cell viability because it is 
a reliable and effective method based on the reduction 
of yellow tetrazolium salts by mitochondrial reductases 
of metabolically active cells. Blue crystals are formed 
intracellularly; they are solubilized and then analyzed 
by UV-VIS spectrophotometry. Thus, the lower the 
cell viability is, the lower the MTT reduction and spec-
trophotometric signal will be [16]. The trypsinized cells 
were previously plated in 96-well plates (Sarstedt, Inc.) 
in a standardized amount of 1 × 105 cells per well, in 
triplicates. Then, 195 μl culture medium, prewarmed 
at 37°C and 5 μl of MTT (10 mg/ml) per well were 
added. The cells were incubated for 2 h away from 
light. Supernatant was removed by inverting the micro-
plate. Thereafter, 200 μl of DMSO (Sigma,  Brasil) 
were added to dissolve the crystals, and the plates were 
shaken in an orbital vortex. Finally, absorbance read-
ing was carried out at a wavelength of 570 nm using a 
spectrophotometry reader. The procedure was similar 
at all fixed intervals: 7, 14, 21 and 28 days.
Mineralization assay 
von Kossa
We used the von Kossa method in this study because 
it allows the identification of mineralized tissues in a 
sample. It is based on the binding of silver (Ag2) to 
calcium. Eosin is a counter-stain that highlights the 
nodule. Initially, cells were plated in four 6-well plates 
(Sarstedt, Inc.), identified on days 7, 14, 21 and 28, 
1 × 106 cells per well.
At different fixed intervals of time, the three upper 
wells of each well plate were washed up twice with 
1 ml of distilled water, and then 1 ml of 4% para-
formaldehyde solution was added to each well for 
15 min. Subsequently, paraformaldehyde was dis-
carded and the 6-well plates were washed up three-
times with 1 ml of distilled water; 1 ml of 5% silver 
nitrate was added to each well for 20 min under UV 
light. The 6-well plate was washed up three- to five-
times with distilled water, and thiosulfate 5% was 
added for 2 min. The 6-well plate was washed up 
three- to five-times with distilled water again and 
1 ml of 0.1% eosin was added for 3 min. The 6-well 
plate was washed up once more with distilled water 
and, finally, the analysis under a microscope was 
 performed.
Alizarin red
Alizarin Red method was adopted in this study because 
it also allows the identification of mineralized tissues 
in a sample, based on the binding of silver (Ag2) to 
calcium. It is a dye used to confirm the results found 
with the von Kossa method. For the dye preparation, 
alizarin red (Sigma-Aldrich) was diluted in a ratio 
of 2 g/100 mg of distilled water. Initially, cells were 
placed in four 6-well plates (Sarstedt, Inc.), identified 
on 7, 14, 21 and 28 days, 1 × 106 cells per well. At 
different fixed time intervals, the three lower wells of 
each well plate were washed up three-times with phos-
phate-buffered saline (LGC Biotecnologia). Following, 
1 ml of 10% formaldehyde was added into each well 
for 30 min, and then each well was washed with 1 ml 
of distilled water. Alizarin red was added to the wells 
and the plate was maintained in an orbital shaker for 
10 min and then washed up with distilled water.
The calcified nodules formed after the von Kossa 
and alizarin red methods were analyzed macroscopi-
cally and microscopically. The images were obtained 
and the nodules were quantified using AxioVert® 40C 
(Carl Zeiss, Jena, Germany) inverted optical micros-
copy through Software AxioVision®4.1 (Carl Zeiss, 
Jena, Germany). Values were analyzed through Graph-
Pad Prism5® (GraphPad Software, São Paulo, Brazil) 
statistical program using the two-way analysis of vari-
ance (ANOVA). The software ImageJ was used to 
measure the nodules, and the number of nodules per 
well was obtained for every standard size in the study. 
All analyses were conducted at fixed intervals of 7, 14, 
21 and 28 days.
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Statistical analysis
Results were assessed by Friedman’s χ2 test to compare 
the proliferation value obtained over time (7, 14, 21 
and 28 days), and the test was performed separately 
for each group. Cell viability analysis was performed 
using the Prisma5 statistical program and t-test analy-
sis. Quantification of mineralized nodules found in 
the sample was performed by GraphPad Prism5® sta-
tistical program using the two-way ANOVA, and the 
nodule’s size was measured using software ImageJ. The 
 rejection level of the null hypothesis was set at 5%.
Results 
Cell proliferation using trypan blue method
Protocol A cells (no DEX) had proliferation peak on 
day 21, declining thenceforth. Protocol B cells (with 
4 mg DEX) had proliferation peak on day 14, declin-
ing thenceforth (Figure 1). For statistical assessment of 
proliferation by trypan blue, we used the Friedman’s test, 
which is a nonparametric estimate for the comparison of 
the variables over time, with software BioStat. The results 
in Protocol A showed that cell proliferation reached a 
proliferation peak on day 21 of culture, obtaining a sta-
tistically significant value: p = 0.0421, while in Proto-
col B, proliferation was higher on day 14, also showing a 
statistically significant value of p = 0.0421 (Table 1).
Human dental pulp stem cell viability  assessment
Following plating in 96-well plates, in triplicate, 
cells were read in a spectrophotometer. Analyses 
were performed and graphs were designed comparing 
groups and intervals. Statistical analysis was carried 
out using GraphPad Prism5® statistical program. 
Protocol A cells (no DEX) were statistically more 
viable on days 7 and 21, while Protocol B cells (with 
DEX) were statistically more viable after day 14. On 
day 28, no  statistically significant value was found 
(Figure 2).
Mineralization assay 
von Kossa & alizarin red
After plating the cells in 6-well plates, von Kossa stain-
ing and alizarin red were used for examining possible 
mineralized nodules. In the three upper wells, we used 
von Kossa stain and in the three lower wells, alizarin 
red. This procedure was performed in all samples and 
were equally reproduced at intervals of 7, 14, 21 and 
28 days. In Protocol A, the presence of mineralized 
nodule was not identified on day 7, either with von 
Kossa stain or alizarin red (Figure 3). On days 14, 21 
and 28, we observed the formation of mineralized nod-
ules. In Protocol B, the presence of calcified nodules was 
observed in all fixed intervals, namely 7, 14, 21 and 28 
Figure 1. Comparison chart between Protocols A and B. Proliferation curves between Protocols A (no DEX) and B 
(with DEX), expressed as number of cells per million versus time (intervals of the analysis). In Protocol A, cell 
proliferation peaked on day 21 and as early as day 14 in Protocol B.
DEX: Dexamethasone.
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days, both with the von Kossa and alizarin red assays. 
In addition, the nodules were larger and mineralized 
sooner in Protocol B, on day 7, when compared with 
Protocol A (Table 2), which is consistent with results 
found in the literature [14]. The statistical analysis used 
for counting nodules was two-way ANOVA, and the 
number of nodules found in Protocol A and Protocol B 
was statistically significant (Figure 4), p < 000.1.
Discussion
Tooth development occurs as a result of the interac-
tions between mesenchymal cells and epithelial ones. 
These interactions will first originate the enamel 
organ and, following, the papilla and dental fol-
licle [17]. The other components of the tooth, such as 
dentin, pulp, cementum and the periodontal ligament 
will be developed by MSCs [17,18]. MSCs constitute a 
source of study in several experiments involving labo-
ratory cell culture. Those cells have highly variable 
proliferation rate, depending on the formulation of 
the medium (basal media and supplements), the den-
sity of cell seeding, the substrate area and the phys-
ical-chemical environment [17], and may be found 
in various areas of the human body and in various 
dental tissues, among them the dental pulp of per-
manent teeth, also known as dental pulp stem cells, 
(DPSCs) [19,20]. DPSCs are capable of self-renovating 
and differentiating in osteoblasts, adipocytes, neural 
cells and odontoblasts [19,20].
In this study, we used third molar dental pulps 
because they are a rich source of cells used in dental 
science experiments. Research has shown that devel-
opmental stages 2–3 of third molar teeth have larger 
quantity and better quality of stem cells [8]. However, 
some difficulties regarding the tooth extraction tech-
nique at this stage of development often restrict the 
sample number and make the surgery more traumatic. 
In this sense, there are medications – amoxicillin and 
DEX – used as a protocol in dental practice that may 
minimize the effects produced by the surgical trauma. 
Amoxicillin is an effective antibiotic for reducing the 
incidence of alveolitis and, additionally, provides better 
results in mouth opening after surgery [10] and prevents 
postoperative wound infection. DEX is one of the most 
potent synthetic glucocorticoids used as an adjunctive 
therapy in many diseases because it has good anti-
inflammatory, immunosuppressive and antiexudative 
properties [13,21]. It is used in several protocols, such as 
preoperative medication in third molar surgery due to 
its beneficial effects, namely inflammatory symptoms 
reduction, operative sequelae, such as early and late 
edema, trismus and pain decrease [21–23].
The use of DEX 1 h prior to surgery is justified 
by several studies that have evaluated its pharmaco-
kinetics and found that its maximum effect is 
achieved from 1 to 2 h after oral administration [13]. 
Accordingly, the medication will be making the 
desired effect during the surgical procedure. Despite 
Table 1. Table showing statistical analysis of cell proliferation.
Days
Protocol A (no dexamethasone)
  7 14 21 28
Sample 1 4.0 9.5 10 5.5
Sample 2 4.8 15 16 6.5
Sample 3 9.5 18 34* 21
X 6.1 14.17 20.0 11.0
χ2 = 8.20 v *p = 0.0421 21 dias > 7 dias
Protocol B (with dexamethasone)
 7 14 21 28
Sample 1 5.5 7.5 6.5 5.0
Sample 2 4.0 9.5 5.5 4.6
Sample 3 6.1 15* 14 13
X 5.2 10.7 8.7 7.5
χ2 = 8.20 *p = 0.0421 14 dias > 7 dias
The table shows the number of cells in million obtained at intervals of 7, 14, 21, and 28 days in each sample (six teeth). Protocol A (no DEX) 
showed cells reaching a proliferation peak on day 21 of culture and obtaining a statistically significant value: *p = 0.0421. Protocol B (with 
DEX) had the highest proliferation on day 14 of culture, also obtaining a statistically significant value of *p = 0.0421.
DEX: Dexamethasone.
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all its desirable effects, however, when systemically 
used in mice for a prolonged period of time, DEX 
produces metabolic side effects, such as insulin resis-
tance, hypertension, glaucoma and osteoporosis [24]. 
Similarly, studies have shown that long-term use of 
DEX in humans also leads to bone loss and conse-
quent osteoporosis [25–27] because it suppresses osteo-
blast function, reduces intestinal calcium absorption, 
increases bone resorption and  suppresses endogenous 
gonadal steroids [26,27].
In addition to being used as a drug, DEX is widely 
used and added to culture media as an osteoinduction 
factor [12,15,19,28]. Considering that tissue engineering 
involves applying its techniques with the aim of devel-
oping biological substitutes that will restore, improve 
or maintain tissue function [1], and knowing that 
DEX induces osteogenic development when added 
to the culture medium [12,15,19,28], it is of the utmost 
importance to understand the in vitro cell behavior 
when the patient is given that medication, whose use 
is included in dental practice protocols. Therefore, the 
main purpose of this study was to evaluate the osteo-
inductive effect of DEX administered as a preoperative 
 medication in primary cell culture of hDPSCs.
Figure 2. Cell viability assay. Viability by methylthiazol tetrazolium. The values were obtained from the analysis of 
t-test. The cells were statistically more feasible on days 7 (A) and 21 (C) in Protocol A, while Protocol B cells were 
statistically more viable after 14 (B) days of culture. (D) A statistically significant value was not obtained on day 28.
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The experimental design of this study was based on 
fundamental preliminary experiments and aimed to 
characterize it in terms of reproducibility and repeat-
ability. The methodology was based on cell culture in 
order to characterize the cells according to incubation 
time, temperature, appropriate cell culture conditions, 
linearity and time interval analysis. The cells obtained 
from third molars pulp were evaluated for prolifera-
tion, viability and formation of calcified nodules. We 
compared cultures from the first surgical session, when 
patients had not received DEX, with the cell culture 
from the second surgical session, when patients took 
in DEX. Two surgical sessions had been performed 
with a 15-day interval between surgeries for the same 
patient. In order to eliminate any bias, we compared 
the cells of the same donor, and the medication was 
the only variable. Additionally, assuming that DEX is 
a routinely used drug in dentistry and knowing that it 
produces an osteoinductive effect when added to cul-
ture medium [20–24], our goal was to evaluate whether 
it would have an effect on the culture of cells obtained 
from the stem cells from third molar dental pulp. We 
used time intervals of 7, 14, 21 and 28 days in our study.
DEX is an SAID that influences transcription of 
various genes and changes mRNA synthesis, which 
generate the proteins that will mediate multiple 
physio logical effects in the bone [29,30]. In the body, 
DEX plays an anti-inflammatory role since it acts 
in various inflammation events, reducing, for exam-
ple, the onset of tenascin-C, present in extracellular 
matrix of adult individuals’ injured tissues [31]. In 
addition, by blocking phospholipase A2 (that is an 
enzyme that promotes arachidonic acid release into 
cell wound), the angiogenesis, synthesis of leukot-
rienes and PGs decrease [31,32]. PGs, which may, in 
some circumstances, stimulate bone resorption, are 
also responsible for mediating major events related 
to both bone formation and repair [30,33] and play an 
important physiological role by enhancing bone for-
mation as a response to a mechanical stimulus, both 
in animals and humans [34]. Moreover, PGs, espe-
cially PGE2, are produced by osteoblasts under the 
stimulation of COX2, whose expression is controlled 
by hormones, cytokines and growth factors respon-
sible for bone remodeling. SAIDs inhibit transcrip-
tion of several cytokine genes, such as IL-6 [30]. IL-6 
Figure 3. Analysis using von Kossa and alizarin red. Analysis between Protocols A (no DEX) and B (with DEX) 
regarding von Kossa and alizarin red stains, and calcified nodules formation in time slots 7, 14, 21 and 28 at 10×. 
On day 7, the presence of mineralized nodules was not observed in Protocol A with both von Kossa (1A) and 
alizarin red (2A) stains. On days 14, 21 and 28, the presence of calcified nodules (arrows) was found in Protocols A 
and B in both samples von Kossa (1B–1H) and alizarin red (2A–2H), bar = 50 mμ.
DEX: Dexamethasone.
Von Kossa Alizarin red
Protocol A
7
14
21
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and -11 stimulate resorption as well as bone formation 
because oesteoclasts, in addition to their osteolytic 
function, play an important role in bone growth and 
development [35]. In this sense, in vivo bone formation 
is clearly a complex dynamic process, involving the 
actions of multiple morphogens, growth factors and 
hormones [36].
In in vitro experiments, DEX has been described in 
several studies as an osteoinductive factor in many dif-
ferent cell types [12,15,19,28,37], including mesenchymal 
cells, human bone marrow derived stromal cells [38], 
fetal rat calvarial cells [39], mouse embryo derived 
NIH3T3 fibroblasts [14,40] and human periodontal 
cells [37]. However, the mechanisms describing how 
DEX is modulated are still unclear [28,37]. Previous 
studies demonstrated that glucocorticoids, including 
DEX, regulate gene expression in differentiating cells 
and induce the affinity of the glucocorticoid recep-
tor for its target sequence in the genome [28,41,42,28]. 
In this sense, the steroid hormone receptors activate 
specific gene transcription by binding as hormone–
receptor complexes to short DNA enhancer-like ele-
ments termed hormone response elements [41,42]. 
According to Lian and Stein, osteoblastic differen-
tiation in vitro is marked by three distinct stages of 
cellular activity: proliferation, extracellular matrix 
maturation and matrix mineralization [43]. The first 
stage is characterized by the high mitotic capacity of 
progenitor cells, represented by the expression of the 
cell growth associated genes, H4 histone and c-fos [44]. 
Due to this proliferative capacity, genes are expressed 
at peak levels. These genes are related to extracellular 
Table 2. Effects of dexamethasone on nodule formation.
Size of nodule 
(μm2)
Time/days
7 14 21 28
Protocol A (no DEX) 
von Kossa     
– 0–9999  4   
– 10,000–19,999  4 12  
– 20,000–29,999   4 3
– >30,000   4 26
Protocol B (with DEX) 
von Kossa     
– 0–9999     
– 10,000–19,999 7  13 7
– 20,000–29,999 3 14 10 16
– >30,000 1 9 31 47
Protocol A (no DEX)
Alizarin red     
– 0–9999  3   
– 10,000–19,999 4 2 8  
– 20,000–29,999 1 12 12  
– >30,000  2 6 12
Protocol B (with DEX)
Alizarin red     
– 0–9999     
– 10,000–19,999 10 7 7 10
– 20,000–29,999 2 13 16 18
– >30,000 1 16 37 46
The table shows the size mean of nodules measured by software ImageJ. The same procedure was performed both in Protocol A (no DEX) 
and Protocol B (with DEX) with both stains.
DEX: Dexamethasone.
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matrix formation [45]. Studies have demonstrated that 
MSCs, once cultured in DEX-supplemented medium, 
start a cascade of development, defined by the acquisi-
tion of cuboidal osteoblastic morphology, transitory 
induction of alkaline phosphatase production, bone 
matrix protein mRNAs expression and biomineraliza-
tion [46]. In bone marrow stromal cells, a number of 
compounds can induce osteoblastic differentiation, 
however, the earliest-known and most readily avail-
able inducer of bone marrow stromal cell differentia-
tion is DEX, that reliably stimulates the development 
of many, although not all, phenotypic characteristics 
of osteoblasts [38,47]. However, the effects of DEX 
on osteoprogenitor cell proliferation and phenotypic 
development also depend on both the dosage and 
 timing of treatment [12,48]
Dental pulp cells can also be induced to express 
odontoblast-like markers when cultures are supple-
mented with DEX, but there are few available data on 
the specific effects of this glucocorticoid on dental pulp 
cells [49]. In order to examine DEX influence on dental 
pulp cultures, studies have focused, for example, on the 
analysis of alkaline phosphatase levels [14], and mRNA 
encoding for dentin sialophosphoprotein [49], cell pro-
liferation [12,50], mineralization potential ( alizarin red 
method) and flow cytometry [50].
In this study, we performed proliferation assays in 
order to identify possible effects of DEX on third molar 
DPSCs. The way DEX contacted the dental pulp cells 
in Protocol B (with DEX) may be inferred by the fact 
that the drug was producing effects in the plasma, 
that is, its maximum effect 1–2 h after oral adminis-
tration [13], during the surgical procedure. Both tissue 
removal and processing prevented the cells, dislodged 
from the explants, from suffering interferences occur-
ring in the body, such as, enzyme action [30] and other 
complex dynamic processes [36]. All cells used in the 
different protocols are third molar cells, characterized 
as cells with a high level of clonogenicity and prolif-
eration, and the ability to generate densely calcified 
colonies and occasional nodules [51]. In this sense, our 
results sustain such assertion and show differentia-
tion in both protocols, with Protocol B (with DEX) 
 standing out because its cells differentiated earlier.
Assessment of cell proliferation was performed using 
trypan blue dye [52], and the cells were counted in an 
automatic counter to avoid the observer’s bias. The 
results showed that Protocol A (no DEX) cell prolifera-
tion peaked on day 21, while Protocol B (with DEX) 
cell proliferation peaked on the 14th day of culture 
(Figure 1). Friedman’s ANOVA was performed and 
the results were statistically significant on day 21 for 
Protocol A and on day 14 for Protocol B (Figure 2). 
After the peak of proliferation, the cells in both pro-
tocols fell into decline according to the classification 
found in another study [53]. These results confirm other 
in vitro studies in which DEX was shown to decrease 
proliferation when added to primary explants [54]. In 
this sense, the presence of DEX is inhibitory to cell 
proliferation, suggesting that DEX acts to direct osteo-
progenitor cells from a state of proliferation to that of 
matrix maturation [12].
For cell viability, we performed the t-test using 
Prisma5 program. There was a statistically significant 
difference in viability of Protocol A cells (no DEX 
intake) on days 7 and 21, whereas Protocol B (with 
Figure 4. Comparison chart of the number of nodules regarding time-nodule formation time in Protocol A (no 
dexamethasone) and Protocol B (with dexamethasone) with the two stains: alizarin red and von Kossa. The 
numbers of nodules were counted at the fixed intervals and analyzed by GraphPad Prism5® statistical program 
using the two-way analysis of variance. Values are presented as mean ± SD of the samples in triplicate. Statistical 
significance between Protocol A and B, both with von Kossa and alizarin red stains is represented as *p < 0.001.
DEX: Dexamethasone.
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DEX) showed a statistically significant difference on 
day 14 in culture (Figure 3). In order to observe cell dif-
ferentiation in mineralized tissues, we used alizarin red 
and von Kossa stains, as described by Puchtler et al. [55]. 
Our results have shown that cells from the teeth of those 
patients who had received DEX 4 mg 1 h prior to sur-
gery differentiated earlier – a 7-day culture – compared 
with the cells of those patients who had not taken any 
medication, being consistent with another study that 
has also examined mineralized nodules formation in 
pericyte cells on the first week of exposure to DEX [14].
In this sense, we can infer that the drug was still 
in action in blood plasma, corroborating studies that 
have demonstrated that the drug reaches its maximum 
effect between 1 and 2 h after oral intake [13]. We have 
also observed that there was higher mineralization 
in Protocol B samples (with DEX) when compared 
with Protocol A samples (no DEX), thus confirming 
previous in vitro studies that showed higher mineral-
ization in samples exposed to DEX in comparison to 
those that did not receive DEX [12]. It is believed that 
mineralization is regulated by deposition of negatively 
charged matrix proteins, and prolonged exposure to 
DEX may correspond to a transition from matrix mat-
uration to mineralization [12,45]. Our data were con-
sistent with those from another study which observed 
that glucocorticoids increase the number and size of 
bone nodules formed in primary bone cell cultures [38] 
and mineralized earlier in the presence of DEX [14], 
Protocol B, compared with Protocol A. In addition, 
it was possible to relate the DEX osteoinductive effect 
when directly added to culture media [12,15,19,28] to the 
systemic application of the drug, which produced the 
same osteoinductive effect.
We have shown that DEX intake produced an 
osteoinductive effect on hDPSC. However, it is not yet 
known how the drug reaches the third molar region.
More importantly, our results show that it is funda-
mental to understand cell behavior in these conditions. 
Once we know that DEX intake promotes cell differen-
tiation within 14 days in culture, all procedures aiming 
to obtain undifferentiated cells should be performed 
with cells cultured for a time period less than 14 days.
Conclusion
The use of DEX as a preoperative medication in third 
molar surgery promotes cell differentiation earlier, when 
observed in vitro. For that reason, when the protocol 
with preoperative DEX is applied, cells must be used 
prior to 14 days in culture in future clinical  applications.
Future perspective
This study is a first approach toward assessing the 
in vitro effects produced by systemic DEX. Issues, such 
as the type of mineralized tissues (dentine, enamel, 
cementum, bone) that cells expressed and how DEX 
was capable of reaching dental pulp cells still need to 
be investigated.
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Executive summary
•	 Dexamethasone (DEX) is widely used and added to culture media as an osteoinductor.
•	 Several studies exist that add DEX directly to cell culture to promote osteoinduction in various types of cells. 
However, no reports can be found in the literature demonstrating its effects on the cells when administered 
as preoperative medication.
•	 Unlike what can be found in the literature, this is not a study from the lab to the clinic; conversely, it is a study 
from the clinic to the lab, which makes it unique.
•	 DEX used as preoperative medication was capable of producing osteoinductor effect in human dental pulp 
stem cell observed in vitro.
•	 When patients took in DEX prior to third molar surgery, we observed that in vitro cells differentiated earlier 
(7 days) than the cells of the same patients when they did not take in DEX (as seen in Figure 3).
•	 The number of mineralized nodules was significantly higher in Protocol B (with DEX) than in Protocol A (no 
DEX).
•	 Protocol A cells reached proliferation peak on day 21 and then began to decline while Protocol B cells peaked 
on day 14 and started to decline thereafter.
•	 This preliminary study may signal that other preoperative drugs also have effects on cell culture because there 
is evidence of changes in cultured cell behavior that is worth investigating with other drugs.
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